Kunming, China, June 29, 2023
KBI has a large colony of obese NHP models readily available for the needs of research services.
We routinely evaluate anti-obese efficacy with a wide range of tools including the following techniques:
· measurements of caloric intake and body mass index (BMI)
· quantification of body fat composition with dual energy X-ray absorptiometry (DEXA and iDXA)
· measurement of ectopic fat accumulation with magnetic resonance imaging (MRI)
· molecular biomarkers (such as adipokine mRNA expression) from fat biopsy in the area of interest
· profiling of different subtypes of obesity, including central vs subcutaneous obesity, “leptin sensitive” vs “leptin resistant” obesity
· biopsy of fat tissue for the assessment of adipose browning
![obese 01.jpg obese 01.jpg](/upload/image/2023/06/02/6382131468901323732258759.jpg)
Fig 1. Quantification of fat distribution of monkeys by iDEXA at KBI.
![obese 02.jpg obese 02.jpg](/upload/image/2023/06/29/6382364445115459811641098.jpg)
Fig 2. Profiling of obese monkeys into leptin sensitive and leptin resistant subtypes at KBI.
Further, we have successfully provided successful services for the evaluation of anti-obese drugs with associated diseases at different stages including:
· dyslipidemia (including triglyceride, cholesterol, LDL-C, HDL-C and lipoproteins)
· pre-diabetes, diabetes and diabetic complications (such as diabetic chronic kidney disease)
· non-alcoholic fatty liver disease
· cardiovascular disease (such as hypertension and heart failure)
Contact us if you need more information.